AbbVie’s Humira strategy to be scrutinised in first evergreening unclean hands challenge

In a Delaware case Boehringer Ingelheim accuses the Illinois company of improper conduct in deliberately constructing a patent thicket to protect against generic versions of its blockbuster drug.


Get unlimited access to all IAM content